Takeda Expands its Own Sales and Marketing Operations in Europe

Osaka, Japan & London, March 30, 2009 – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) and its wholly-owned UK-based subsidiary for overseeing pan-European sales & marketing, Takeda Pharmaceutical Europe Limited (London, UK, “TPEU”) jointly announced today the start of its own sales and marketing operations in Spain, and also the expansion of its operations in the Republic of Ireland to cover the entire country, which used to be limited in a specific area.

In Spain, the fifth largest pharmaceutical market in Europe, Takeda Farmacéutica España S.A., a wholly-owned subsidiary of Takeda, will start promotional activities for Blopress® (generic name; candesartan cilexetil) and Glustin® (generic name: pioglitazone HCl, known in Japan, U.S. and other European markets as Actos®). In the Republic of Ireland, Takeda’s wholly-owned subsidiary, Takeda UK Limited already expanded promotional activities for Actos in January this year.

“We are pleased with the expansion of geographical coverage in Spain, one of the most important markets in Europe, and also the nationwide coverage in the Republic of Ireland,” said Eric Brunn, CEO of TPEU. “We will actively introduce products from our portfolio into these two countries, so that they will help many more patients suffering from a variety of diseases”.

“The commencement of our own sales and marketing operations in Spain and the Republic of Ireland is contributing to one of our key management initiatives, namely the enhancement of our presence in each region of the world to further establish Takeda as a world-class pharmaceutical company”, said Yasuchika Hasegawa, President of Takeda. “Through our continued efforts for geographical expansion in Europe, we anticipate that our European business will represent further more significance as well as our business in Japan and the United States.”

Takeda now has its own sales and marketing operations in eight European countries: in addition to Spain and Ireland, there are wholly-owned subsidiaries in France, UK, Italy, Germany, Austria and Switzerland.

About Takeda Farmacéutica España S.A.
Name: Takeda Farmacéutica España S.A.
Location: Barcelona, Catalonia, Spain
Established: January 2008
Capital Stock: Euro 3 million (as of March 30, 2009)

 
About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, www.takeda.com.

About Takeda Pharmaceuticals Europe Limited (TPEU)

Bsed in London, UK, TPEU supports and leads the overall business activities of Takeda’s marketing activities in eight countries in Europe[ * ] by promoting pan-European sales and marketing strategies.

[ * ]Laboratoires Takeda (France), Takeda UK Limited (UK and Ireland),

Takeda Italia Farmaceutici S.p.A. (Italy), Takeda Pharma GmbH (Germany),
Takeda Pharma Ges.m.b.H (Austria), Takeda Pharma AG (Switzerland),
Takeda Farmacéutica España S.A. (Spain)

Contacts:
Takeda Pharmaceutical Company Limited
  • Seizo Masuda
  • Public and Investor Relations
  • +81 3 3278 2037
  • masuda_seizo@takeda.co.jp
Takeda Pharmaceuticals Europe Limited
  • Richard Kenyon
  • Communications Manager
  • +44 20 3116 8861
  • +44 7831 569940
  • richard.kenyon@tpeu.co.uk

Posted: March 2009


View comments

Hide
(web3)